HDAC9 and triple-A syndrome: However, we observed that MS-275, a class I HDAC inhibitor in ongoing clinical trials for oncological diseases, retards death episodes and, more interestingly, under our experimental approach, MC-1568 completely prevented mortality and reduced AAA severity.